{"created":"2023-07-27T06:31:55.852950+00:00","id":17541,"links":{},"metadata":{"_buckets":{"deposit":"8770d36e-c7c2-499e-8518-f0dda925627f"},"_deposit":{"created_by":3,"id":"17541","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"17541"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00017541","sets":["1132:1137:1270:1358"]},"author_link":["31135"],"item_7_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1995-12-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"667","bibliographicPageStart":"655","bibliographicVolumeNumber":"104","bibliographic_titles":[{"bibliographic_title":"金沢大学十全医学会雑誌"}]}]},"item_7_description_16":{"attribute_name":"その他の識別子","attribute_value_mlt":[{"subitem_description":"1996196893","subitem_description_type":"Other"}]},"item_7_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"1)ヒト多剤耐性遺伝子産物P糖蛋白に対するマウス-ヒトキメラ抗体と3種類のサイトカインIL-2, IL-4, GM-CSFとの融合蛋白を作製した. 2)作製した融合蛋白はサイトカイン分子としての活性を保持していた.IL-2, IL-4融合抗体は組換え体IL-2と比較して比活性が減弱していたが,GM-CF融合抗体は組換え体GM-CSFと同等の比活性を維持していた. 3)試験管内で抗腫瘍活性を調べた結果,3種類のサイトカイン融合キメラ抗体はいずれもADCC活性を保持し,作動細胞/標的細胞比依存性に細胞傷害活性の増強効果を示した.MH-16-mIL-2, MH16-mGM-CSFは対照としたMH16と比較して傷害活性の増強効果を認めた. 4)生体内での腫瘍移植実験で3種類のサイトカイン融合キメラ抗体はいずれも対照群と比較して有意な腫瘍増殖抑制効果を示した","subitem_description_type":"Abstract"}]},"item_7_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学 医 第3内科","subitem_description_type":"Other"}]},"item_7_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"金沢大学十全医学会"}]},"item_7_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00044397","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0022-7226","subitem_source_identifier_type":"ISSN"}]},"item_7_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"織本, 健司"}],"nameIdentifiers":[{"nameIdentifier":"31135","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-04"}],"displaytype":"detail","filename":"AN00044397-104-064.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN00044397-104-064.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/17541/files/AN00044397-104-064.pdf"},"version_id":"2a416589-5595-4d71-93e4-39b12311a1cc"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cytokines","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍抗原","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍抗体","subitem_subject_scheme":"Other"},{"subitem_subject":"モノクローナル抗体","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍(治療,抗原・抗体・補体)","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"サイトカイン融合腫瘍特異的モノクローナル抗体を用いた新しい腫瘍ターゲティング療法の開発に関する基礎的研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"サイトカイン融合腫瘍特異的モノクローナル抗体を用いた新しい腫瘍ターゲティング療法の開発に関する基礎的研究"}]},"item_type_id":"7","owner":"3","path":["1358"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-04"},"publish_date":"2017-10-04","publish_status":"0","recid":"17541","relation_version_is_last":true,"title":["サイトカイン融合腫瘍特異的モノクローナル抗体を用いた新しい腫瘍ターゲティング療法の開発に関する基礎的研究"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:01:50.502530+00:00"}